Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$229
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
ARA 290 is a non-hematopoietic cyclic peptide (11 residues) derived from the helix B surface of erythropoietin (EPO) that selectively engages the innate repair receptor (IRR) — a heterodimer of the β-common receptor (βcR) and the EPO receptor (EPOR).
ARA 290 is particularly valuable in experiments designed to separate EPO's tissue-protective functions from its erythropoietic actions. Research designs typically include full EPO, ARA 290, and IRR-selective antagonists as comparative conditions to attribute specific readouts to each receptor complex.
Browse Inventory
In research literature, ARA 290 is generally treated as a non-hematopoietic cyclic peptide (11 residues) derived from the helix B surface of erythropoietin (EPO) that selectively engages the innate repair receptor (IRR) — a heterodimer of the β-common receptor (βcR) and the EPO receptor (EPOR). ARA 290 reproduces the tissue-protective signalling of erythropoietin without binding the homodimeric EPOR complex responsible for haematopoiesis, enabling research into EPO's non-erythropoietic functions. The β-common receptor (CD131)/EPOR heterodimer (IRR) activates PI3K/Akt and MAPK signalling pathways upon ARA 290 binding, producing anti-inflammatory, anti-apoptotic, and neuro-protective readouts in relevant cell models. Because it does not engage the canonical EPOR homodimer, it can be used in haematopoietic models without confounding red cell lineage effects.
ARA 290 is particularly valuable in experiments designed to separate EPO's tissue-protective functions from its erythropoietic actions. Research designs typically include full EPO, ARA 290, and IRR-selective antagonists as comparative conditions to attribute specific readouts to each receptor complex. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether ARA 290 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for ARA 290 should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for ARA 290 is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare ARA 290 with NAD+, PT-141, and Glow, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 1 labelled variant: 10mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
ARA 290 is generally discussed as a non-hematopoietic cyclic peptide (11 residues) derived from the helix B surface of erythropoietin (EPO) that selectively engages the innate repair receptor (IRR) — a heterodimer of the β-common receptor (βcR) and the EPO receptor (EPOR). The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
